Aging and Health - A Systems Biology PerspectiveEditor(s): Yashin A.I. (Durham, N.C.)
Jazwinski S.M. (New Orleans, La.)
Modulating mTOR in Aging and HealthJohnson S.C. · Sangesland M. · Kaeberlein M. · Rabinovitch P.S.
Department of Pathology, University of Washington, Seattle, Wash., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The physiological responses to nutrient availability play a central role in aging and disease. Genetic and pharmacological studies have identified highly conserved cellular signaling pathways that influence aging by regulating the interface between nutrient and hormone cues and cellular growth and maintenance. Among these pathways, the mechanistic target of rapamycin (mTOR) has been most reproducibly shown to modulate aging in evolutionarily diverse organisms as reduction in mTOR activity extends life span from yeast to rodents. mTOR has been shown to play a role in a broad range of diseases, and is of particular interest to human health and aging due to the availability of clinically approved pharmacological agents targeting the mTOR complexes and other components of the mTOR signaling network. Characterizing the role of mTOR in aging and health promises to provide new avenues for intervention in human aging and disease through modulation of this signaling pathway.
© 2015 S. Karger AG, Basel
- Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, Faucette L, Eng WK, Johnson RK, Livi GP: Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol 1993;13:6012-6023.
- Chiu MI, Katz H, Berlin V: RAPT1, a mammalian homolog of yeast TOR, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 1994;91:12574-12578.
- Fabrizio P, Pozza F, Pletcher SD, Gendron CM, Longo VD: Regulation of longevity and stress resistance by Sch9 in yeast. Science 2001;292:288-290.
- Jia K, Chen D, Riddle DL: The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 2004;131:3897-3906.
- Johnson SC, Rabinovitch PS, Kaeberlein M: mTOR is a key modulator of ageing and age-related disease. Nature 2013;493:338-345.
- Kenyon CJ: The genetics of ageing. Nature 2010;464:504-512.
- Huang J, Manning BD: The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-190.
- Xie X, Guan KL: The ribosome and TORC2: collaborators for cell growth. Cell 2011;144:640-642.
- Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214-226.
- Björntorp P, Carlström S, Fagerberg SE, Hermann LS, Holm AG, Scherstén B, Ostman J: Influence of phenformin and metformin on exercise-induced lactataemia in patients with diabetes mellitus. Diabetologia 1978;15:95-98.
- Jewell JL, Russell RC, Guan KL: Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 2013;14:133-139.
- Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R: Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev 2012;11:390-398.
- Swindell WR: Dietary restriction in rats and mice: a meta-analysis and review of the evidence for genotype-dependent effects on lifespan. Ageing Res Rev 2012;11:254-270.
- Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C: Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging cell 2007;6:95-110.
- Proud CG: mTORC1 signalling and mRNA translation. Biochem Soc Trans 2009;37:227-231.
- Steffen KK, MacKay VL, Kerr EO, Tsuchiya M, Hu D, Fox LA, Dang N, Johnston ED, Oakes JA, Tchao BN, Pak DN, Fields S, Kennedy BK, Kaeberlein M: Yeast life span extension by depletion of 60s ribosomal subunits is mediated by Gcn4. Cell 2008;133:292-302.
- Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM: A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012;485:109-113.
- Tsukiyama-Kohara K, Poulin F, Kohara M, DeMaria CT, Cheng A, Wu Z, Gingras AC, Katsume A, Elchebly M, Spiegelman BM, Harper ME, Tremblay ML, Sonenberg N: Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nature 2001;7:1128-1132.
- Conn CS, Qian SB: Nutrient signaling in protein homeostasis: an increase in quantity at the expense of quality. Sci Signal 2013;6:ra24.
- Cho S, Hwang ES: Fluorescence-based detection and quantification of features of cellular senescence. Methods Cell Biol 2011;103:149-188.
- Rubinsztein DC, Mariño G, Kroemer G: Autophagy and aging. Cell 2011;146:682-695.
- Jia K, Levine B: Autophagy and longevity: lessons from C. elegans. Adv Exp Med Biol 2010;694:47-60.
- Nixon RA, Yang DS: Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect Biol 2012;4:pii a008839.
- Lee HC, Wei YH: Mitochondria and aging. Adv Exp Med Biol 2012;942:311-327.
- Wouters BG, Koritzinsky M: Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8:851-864.
- Grimm C, Willmann G: Hypoxia in the eye: a two-sided coin. High Alt Med Biol 2012;13:169-175.
- Konisti S, Kiriakidis S, Paleolog EM: Hypoxia - a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol 2012;8:153-162.
- Ristow M, Zarse K: How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp Gerontol 2010;45:410-418.
- Polak P, Cybulski N, Feige JN, Auwerx J, Rüegg MA, Hall MN: Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 2008;8:399-410.
- Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P: mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007;450:736-740.
- Terman A, Kurz T, Navratil M, Arriaga EA, Brunk UT: Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging. Antioxid Redox Signal 2010;12:503-535.
- Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, Herbert RL, Longo DL, Allison DB, Young JE, Bryant M, Barnard D, Ward WF, Qi W, Ingram DK, de Cabo R: Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012;489:318-321.
- Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R: Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009;325:201-204.
- Dai DF, Chen T, Johnson SC, Szeto H, Rabinovitch PS: Cardiac aging: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal 2012;16:1492-1526.
- Kim U, Park JS, Lee SH, Shin DG, Kim YJ: Seven-year clinical outcomes of sirolimus-eluting stent versus bare-metal stent: a matched analysis from a real world, single center registry. J Korean Med Sci 2013;28:396-401.
- Chong ZZ, Shang YC, Wang S, Maiese K: Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol 2012;99:128-148.
- Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB, Austad SN, Strong R, Richardson A, Hart MJ, Galvan V: Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 2012;223:102-113.
- Galanopoulou AS, Gorter JA, Cepeda C: Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 2012;53:1119-1130.
- Ruiz-Falcó Rojas ML: Therapeutic update in tuberous sclerosis complex: the role of mTOR pathway inhibitors. Rev Neurol 2012;54(suppl 3):S19-S24.
- Laplante M, Sabatini DM: mTOR signaling in growth control and disease. Cell 2012;149:274-293.
- Laplante M, Sabatini DM: An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009;19:R1046-R1052.
- Cybulski N, Polak P, Auwerx J, Rüegg MA, Hall MN: mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci USA 2009;106:9902-9907.
- Bell A, Grunder L, Sorisky A: Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res 2009;8:249-254.
- Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA: Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012;335:1638-1643.
- Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, Ford ML, Ahmed R, Kirk AD, Larsen CP: Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant 2011;11:613-618.
- Stahl A, Paschek L, Martin G, Gross NJ, Feltgen N, Hansen LL, Agostini HT: Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 2008;582:3097-3102.
- Kolosova NG, Muraleva NA, Zhdankina AA, Stefanova NA, Fursova AZ, Blagosklonny MV: Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. Am J Pathol 2012;181:472-477.
- Nussenblatt RB, Byrnes G, Sen HN, Yeh S, Faia L, Meyerle C, Wroblewski K, Li Z, Liu B, Chew E, Sherry PR, Friedman P, Gill F, Ferris F 3rd: A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010;30:1579-1587.
- Graziotto JJ, Cao K, Collins FS, Krainc D: Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders. Autophagy 2012;8:147-151.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.